TuHURA Biosciences, Inc./NV (HURA) stock
HURANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.37−0.03 (-2.14%)
Close on Nov 18, 2026Market cap $87.31MP/E –Yield –
TuHURA Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
TuHURA Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.88M. For fiscal 2025 it was $20.53M, up 120.5% from the year before. Over ten years it grew 29.5% a year on average. The highest annual figure on record is $20.53M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.53M | +120.5% |
| FY2023 | Jun 30, 2023 | $9.31M | -38.6% |
| FY2022 | Jun 30, 2022 | $15.17M | +28.4% |
| FY2021 | Jun 30, 2021 | $11.82M | +225.5% |
| FY2020 | Jun 30, 2020 | $3.63M | -0.9% |
| FY2019 | Jun 30, 2019 | $3.66M | – |
| FY2018 | Jun 30, 2018 | -$7.13M | – |
| FY2017 | Jun 30, 2017 | -$5.00M | -248.9% |
| FY2016 | Jun 30, 2016 | $3.36M | +43.5% |
| FY2013 | Dec 31, 2013 | $2.34M | +51.1% |
| FY2012 | Dec 31, 2012 | $1.55M | +47.5% |
| FY2011 | Dec 31, 2011 | $1.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $6.62M | +34.4% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $5.23M | +14.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $6.06M | +191.7% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $4.97M | +147.8% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $4.93M | +139.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $4.58M | +44.5% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.08M | -48.2% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $2.01M | -42.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $2.06M | -47.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $3.17M | -16.4% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $4.00M | -0.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $3.47M | -9.6% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $3.90M | +51.0% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $3.79M | +179.5% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $4.03M | +210.6% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $3.84M | +327.5% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $2.58M | +262.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.36M | +88.2% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $1.30M | +35.2% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $899.00K | +22.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $712.00K | -24.8% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $721.00K | -29.3% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $959.84K | -46.1% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $735.84K | -65.6% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $947.25K | -51.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.02M | -50.6% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.78M | +63.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $2.14M | +91.1% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.93M | +164.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $2.06M | -62.8% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $1.09M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.12M | +42.0% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $732.73K | +21.3% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $5.54M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$790.32K | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $789.19K | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $603.85K | – |
| Q4 FY2013CQ4 2013 | Dec 31, 2013 | -$566.06K | – |
| Q3 FY2013CQ3 2013 | Sep 30, 2013 | -$560.24K | – |
See a number that looks wrong?